“But the one thing new is a wondrous thing. The results
“But the one thing new is a wondrous thing. The results from the one macaque treated with AAV leronlimab is even greater than it appears. A functional cure for HIV would be amazing.”
This blew me away in the call. This and Dr Gluck’s confident chortle from time to time.
Re: HIV cure and Sacha’s prezie however, at least two other items made my neck hairs rise up.
First, probably much more obvious to the doctors on the board, but SIV, the Simian/Macaque version HIV shares the same envelope. So let me say it again another way. SIV has the HIV envelope and therefore would interact with cell membrane receptors such as CCR5 in the exact same way that HIV in humans will. So testing drugs in macaques is the holy grail for HIV research. The HIV envelope makes it so.
Therefore, even though we so far have patient zero to report on in that one little promiscuous as shit Macaque, we can be confident that his little SimianIVirus, with HIV envelope will act the same way concerning binding to CCR5 in humans.
Second, and here I go paraphrasing because the facts don’t matter if you know the story. Regarding the AAV assisted in vivo production of Leronlimab in Macaque patient zero, Jonah Sacha said another amazing thing. After the patient was dosed, the viral load went down right close to zero. But then it bounced back. Even though Leronlimab was being created in the little Master Bater, he got virus coming back. But then…………..
After day 8 or 9, or maybe it was week 8 or 9, the little fuckers virus went back down to zero. And remained at zero. That’s frickin’ incredible…bly positive news to me. I wonder what the blip was about. Which chemotaxis frankly. But incredible.
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Inside PMET Resources' Critical Investor Briefing Now, this is the kind of investor chatter that cuts to the core of PMET's game plan. We're talking the big guns coming out with PMET Resources (TSX: PMET) as they gear up for what's poised to be a tell-all investor teleconference about their Shaakichiuwaanaan Project. Yep, mark your calendars because on Tuesday, November...
Continue Reading
Elong's Strategic Move into Central Asia When a company like Elong Hotel Technology decides to plant its flag in Central Asia, it’s more than just another overseas venture. This brand launch in Almaty is a bold statement—a signal that they're here to shake things up in a region ripe for development but lacking in hotel chains. With only about 20% penetration for local...
Continue Reading
Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...
Continue Reading
myKaarma Offers Time and Convenience Boost with Wash Option When was the last time a car dealership didn't have folks lined up waiting for a wash? Dragging out your car's service longer than a Sunday sermon. But today, myKaarma, the folks behind dealership customer interaction magic, cracked open another bottle of convenience with their latest offering: off-site,...
Continue Reading
Big Changes Ahead for Home Franchise Concepts It's a fresh dawn over at Home Franchise Concepts, and Cory Lyons has been tapped to lead four pivotal brands as their new Brand President. Now, if you're looking at this lineup—Kitchen Tune-Up, Bath Tune-Up, The Tailored Closet, and PremierGarage—you know there's more than just nails and hammers involved. Lyons isn't just...
Continue Reading
Anticipation Builds for The Dixie Group's Q3 Results Ah, the smell of anticipation in the air—it's earnings season again, folks! For those keeping a keen eye, The Dixie Group, Inc. (OTCQB: DXYN) sets the stage for the big unveil of its 2026 third-quarter results. They're rolling out the red carpet for investors on Thursday, November 12, 2026, at 11:30 a.m. Eastern Time,...
Continue Reading
Diving Into Uncharted Waters with Bold Moves MoreBetter is stepping right into the murky, unpredictable world of longevity, peptide, and psychedelic therapies with a fresh initiative—the RWE Co-Investment Program. This isn't your run-of-the-mill study announcement; it's a gutsy leap into largely unexplored areas of patient-reported outcomes and real-world evidence. A...
Continue Reading
Introducing a Heavy-Duty Defender for Lab Systems When it comes to safeguarding central laboratory vacuum systems, you can bet there’s more at play than meets the eye. Mass-Vac, Inc., steps up and doesn't mess around with their latest innovation—the MV Multi-Trap® Vacuum Inlet Trap. Climbing aboard in November 2026, this stout guardian against contamination is out to...
Continue Reading
AI's Lofty Goals Meet Retail's Messy Reality I swear, all this chatter about AI transforming retail sounds grand until you dig into the messy trenches, right? This latest Scandit survey lays it bare: retailers have got their AI visions sprinting ahead of the stock data realities inside their stores. Seems those shiny new systems rely on stock data that matches what's...
Continue Reading
AI Meets Gen Z and Millennials: A Financial Lifeline? Here's an angle you might not expect: young folks are all in for AI, particularly when it comes to navigating banking services. Picture it—18 to 34-year-olds embracing AI far more openly than their older counterparts. We're talking 60% of them valuing 24/7 availability in AI services compared to just 47% of those...
Continue Reading
ws Articles" class="btn" href="https://investorshangout.com/blog/news?page=2">More News Articles